* Third Annual Immunotherapeutics and Vaccine Summit * New Approach to Vaccine Delivery * Significant advantages over Current Vaccine Technologies * Lead Product Candidate-GelVac(tm) Nasal Powder H5N1 (Bird Flue) Influenza Vaccine
IRVING, Texas, Aug. 18, 2008 (GLOBE NEWSWIRE) -- DelSite, Inc. (OTCBB:DSII) today announced Dr. Yawei Ni, Chief Scientific Officer of its wholly-owned subsidiary, DelSite Biotechnologies, Inc., presented data and development status of DelSite's GelVac(tm) nasal powder platform for vaccine delivery at the Cambridge Healthtech Institute's Third Annual Immunotherapeutics and Vaccine Summit held August 13-15, 2008, in Cambridge, Massachusetts.
Dr. Ni's presentation before attendees of the Summit, titled "Nasal Powder: A New Approach to Vaccine Delivery," highlighted the significant advantages of the GelVac(tm) nasal powder platform over current vaccine technologies and provided an update on the development status of its lead product candidate, GelVac(tm) nasal powder H5N1 (bird flu) influenza vaccine. DelSite has completed a series of development activities, including pre-IND meetings with the FDA, animal toxicology studies, and a phase I safety study of GelVac(tm) nasal powder without an antigen.
An IND will be filled this month and a phase I safety and immunogenicity study of this vaccine is planned for the 4th quarter of this year. The advantages afforded by the GelVac(tm) nasal powder technology, including room temperature stability, cold chain-free distribution, and needle-free administration, make this vaccine particularly well suited for influenza pandemic preparedness as well as epidemic control.
Dr. Carlton Turner, CEO of DelSite, Inc. commented, "We believe GelVac(tm) nasal powder represents a significant improvement in vaccine technology by using a natural route of immunization that doesn't require the cold storage, cold chain distribution, and preservatives of current liquid vaccine formulation technologies. We are very excited about bringing this technology close to the clinical stage with our lead candidate -- GelVac(tm) nasal powder H5N1 influenza vaccine. It is a versatile platform technology and can be used for protein and peptide vaccines."
The GelVac(tm) nasal powder is a novel in-situ gelling powder based on DelSite's core technology, GelSite(r) polymer which is a high molecular weight ionic polysaccharide manufactured under cGMP at kilogram scales. Based on this core technology, DelSite has developed three delivery platform technologies, GelVac(tm) nasal powder for nasal delivery of vaccines and therapeutics, GelSure(tm) for injectable delivery of therapeutics, and GPDA(tm) depot adjuvant for injectable delivery of vaccines.
About DelSite
DelSite, Inc. is an ISO 9001-certified, research-based, biopharmaceutical and consumer products company with a core technology based on naturally-occurring complex carbohydrates. DelSite also manufactures and markets consumer products and manufactures quality products for other companies. Manufacturing operations comply with cGMP standards. DelSite is developing its proprietary GelSite(r) technology designed to provide controlled release of peptide and protein-based drugs. Its technology is protected by more than 130 patents in 26 countries. For more information, visit www.delsite.com.
About DelSite Biotechnologies, Inc.
DelSite Biotechnologies, Inc., a wholly own subsidiary of DelSite, Inc., is dedicated to the stabilization of proteins and peptides for therapeutics and vaccines. The GelVac(tm) powder platform is for nasal delivery of vaccines and therapeutics. GelSure(tm) has been developed for liquid delivery and GPDA(tm) is for adjuvant use. Core platform technology is based on a natural polymer.
Certain statements in this release concerning DelSite may be forward-looking. Actual events will be dependent upon a number of factors and risks including, but not limited to: subsequent changes in plans by the Company's management; delays or problems in formulation, manufacturing, distribution, production and/or launch of new finished products; changes in the regulatory process; changes in market trends; and a number of other factors and risks described from time to time in the Company's filings with the Securities & Exchange Commission.